Viewing Study NCT06613035


Ignite Creation Date: 2025-12-24 @ 10:22 PM
Ignite Modification Date: 2025-12-31 @ 9:57 AM
Study NCT ID: NCT06613035
Status: NOT_YET_RECRUITING
Last Update Posted: 2024-09-25
First Post: 2024-09-22
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Twice-per-weekSelinexor, 2 Days Melphalan
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module